Resumen de: WO2022019786A1

Analysis of microRNA (miRNA) signatures to determine or predict stages of cognitive impairment and likelihood of Alzheimer's disease in an individual.

Resumen de: EP4186918A1

The present invention provides inhibitory peptides for use in the diagnostic and/or treatment of tauopathies, in particular Alzheimer's Disease and Pick's Disease. The inhibitory peptides comprise a hexapeptide sequence that specifically inhibits interactions of the PHF6 sequence within pathological Tau protein.

Resumen de: WO2022019786A1

Analysis of microRNA (miRNA) signatures to determine or predict stages of cognitive impairment and likelihood of Alzheimer's disease in an individual.

Resumen de: WO2023091395A1

Aspects of the present invention relate to methods for detecting a lipidated protein in a sample from a subject using a protein binding agent and a lipid binding agent configured for detecting the lipidated protein via a fluorescence resonance energy transfer (FRET) assay. In some aspects, such methods are useful for diagnosing and treating a subject such as a subject having a neurological disorder.

Resumen de: WO2023089062A1

Current application relates to the field of neurodegenerative diseases. Specifically, the present invention relates to screening methods to identify therapeutic candidates for the prevention and/or treatment of Alzheimer's disease. More particularly, said candidates overcome endolysosomal dysfunction resulting from an accumulation of APP- carboxyterminal fragments. The identification /screening methods identify gamma-secretase inhibitors and stabilizers, for which the toxic side effects of endolysosomal dysfunction (lysosomal ca2 + decreased, lysosomal cholesterol build-up) caused by the gamma- secretase inhibition and resulting APP-carboxyterminal fragment accumulation are mitigated, by setting upper limits to the screening assays for these effects. In a second method the downstream toxic effect of lysosomal cholesterol build-up is antagonised by using stimulators of its efflux.

Resumen de: WO2023091907A1

This document relates to methods and materials involved in assessing and/or treating mammals having a neurological autoimmune disorder (e.g., a paraneoplastic neurological autoimmune disorder) and/or cancer. For example, methods and materials for detecting anti-neuronal nuclear antibody type 3 (ANNA3) antibodies are provided.

Resumen de: AU2023202853A1

The present disclosure provides sensor arrays for detecting biomolecules and methods of use. In some embodiments, the sensor arrays are capable of determining a disease state in a subject.

Resumen de: US2023160912A1

Disclosed are an immunoassay method capable of highly sensitively measuring amyloid β in a blood sample, and a kit therefor. The immunoassay method for amyloid β is a method of immunoassay of amyloid β in a blood sample, wherein the immunoassay is carried out in the presence of an anionic polymer such as a dextran sulfate salt or a polystyrene sulfonic acid salt. The kit for immunoassay of amyloid β in a blood sample comprises: an anti-amyloid β antibody or an antigen-binding fragment thereof; and an anionic polymer.

Resumen de: WO2021195750A1

The present invention provides a method of treating or delaying the onset of Alzheimer's disease or other neurological diseases in a patient having or at risk of developing Alzheimer's disease or other neurological diseases comprising administering to the subject an effective amount of an anti-angiogenic agent. In particular, the present invention provides a method of treating and/or delaying the onset of Alzheimer's disease or other neurological diseases by inhibiting Angiopoietin-2 mediated Tie-2 angiogenic pathway comprising administering to the subject an effective amount of an inhibitor of the Angiopoietin-2 mediated Tie-2 angiogenic pathway.

Resumen de: WO2022013286A1

A method for detecting p217+tau in blood-based samples from a subject with high sensitivity, accuracy, and precision. The assay comprises contacting a sample with a capture antibody directed against a p217+tau epitope to bind the capture antibody to p217+tau peptides in plasma to form antibody-peptide complexes, and separately contacting the antibody-peptide complexes with a detection antibody to bind the detection antibody to the antibody-peptide complexes. The amount of p217+tau is determined by detecting the detection antibody. The amount of p217+tau detected is used to determine whether the subject has tauopathy or is at risk of developing tauopathy, or whether the subject has amyloidogenic disease or is at risk of developing amyloidogenic disease when the amount of p217+tau peptides is above a predetermined threshold value. The method has improved sensitivity such that the predetermined threshold value is above a Lower Limit of Quantification and/or Lower Limit of Detection of the assay.

Resumen de: EP4183795A1

The present invention relates to antibody molecules and peptide delivery systems for use in the treatment and management of Alzheimer's disease and related disorders. In particular, the antibody molecules preferentially bind oligomeric forms of beta-amyloid peptide, in single domain format, and the peptide delivery systems facilitate specific transport of such antibody molecules, as well as other cargo molecules, across the blood-brain barrier. The invention also relates to constructs of the antibody molecules and the delivery peptides, as well as pharmaceutical compositions comprising effective amounts of the antibody molecules, delivery peptides, and/or their constructs, including humanized versions of the antibody molecules and constructs. The invention further relates to methods of making these products and pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions in treating or preventing Alzheimer's and related disorders, such as those involving accumulation of beta-amyloid peptide or other peptides that aggregate in the brain; as well as to methods and kits for diagnosing these disorders.

Resumen de: WO2022008712A1

The present invention provides a system for the study of tau protein aggregation in neuronal cells in vitro which can be used to screen agents for therapeutic effectiveness against aggregates of tau protein or fragments thereof.

Resumen de: WO2022008712A1

The present invention provides a system for the study of tau protein aggregation in neuronal cells in vitro which can be used to screen agents for therapeutic effectiveness against aggregates of tau protein or fragments thereof.

Resumen de: WO2022056528A1

Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function.

Resumen de: KR20230065860A

본 발명은 레트로머 안정제를 포함하는 당뇨병 매개 신경퇴행성 질환의 예방, 개선 또는 치료용 조성물 내지 이의 용도를 제공하는 것이다. 본 발명은 고농도 포도당이 VPS26a 감소-매개 레트로머 기능 이상을 통해 아밀로이드 전구 단백질(APP) 및 타우(tau) 단백질의 과인산화를 유발하고, 당뇨 모델 신경세포 또는 마우스에 레트로머 안정제를 투여하는 경우 이를 억제할 수 있음을 확인하였다. 따라서, VPS26a 조절 및 레트로머 안정제의 사용은 당뇨-매개 신경퇴행성 질환의 예방, 개선 또는 치료를 위한 방법 내지 신경퇴행성질환 관련 의약품 분야에 적용될 수 있다.

Resumen de: WO2018178078A1

The invention relates to the identification of a new Tau species starting at residue Met11 (Met11-Tau) which is N-alpha-terminally acetylated form (N-alpha-acetyl-Met11-Tau species: Ac-Met11-Tau). Several monoclonal antibodies specific of this new Tau species have been developed. One of this antibody, 2H2/D11, was used in THY-Tau22 mouse model (that develops with age neurofibrillary degeneration (NFD) and memory deficits), and N-alpha- Ac-Met11-Tau species were clearly detected early in neurons displaying NFD on hippocampal brain sections while it is not reactive in hippocampus from elderly controls. Finally, by using ELISA sandwich specific of Ac-Met11-Tau species, Alzheimer Disease (AD) brain samples are clearly discriminated from human elderly control brains. Thus the invention relates to this new Tau species starting from the methionine residue at position 11 said methionine being N-alpha acetylated. The invention also relates to antibody that specifically binds this new tau species, a method of detection of this new Tau species and a method of diagnosis of Tauopathy disorder.

Resumen de: WO2023080687A1

The present invention relates to a screening kit for an amyloid-beta multimer inhibitory drug, a high-speed mass screening method for a drug for prevention or treatment of Alzheimer's disease by using same, and an inhibitory effect of doxorubicin and a derivative thereof on amyloid-beta. More specifically, it can rapidly and accurately screen for drugs having an inhibitory effect on amyloid-beta multimer from candidate materials, in large quantities, and thus can be usefully utilized for discovering and preempting a drug for preventing or treating Alzheimer's disease, and since doxorubicin or a derivative thereof significantly inhibits oligomerization and fibrillation of amyloid-beta, it can be usefully utilized not only to prevent, ameliorate, or treat Alzheimer's disease, but also to provide information required for the detection of amyloid-beta and diagnosis of Alzheimer's disease.

Resumen de: US2023143011A1

The present disclosure relates to a method to detect or measure circRNAs in a biological sample of a subject. In particular the present disclosure is directed to a method for diagnosing a neurological, neurodegenerative, or neuropathological disease such as Alzheimer's disease, in a subject and comprises the steps of—determining the level of one or more circRNA in a sample of a biological sample of said subject.

Resumen de: US2023144446A1

The invention relates to sets of biomarkers and methods of use thereof for diagnosing, staging, treating, and assessing the response of a treatment for neurocognitive disorders characterised by tau toxicity, such as Alzheimer’s disease.

Resumen de: US2023146038A1

Disclosed are methods, kits and cells for screening an inhibitor of association between candidate binding partners, such as for screening antagonists of amyloid peptides. The methods, kits and cells employ a reporter expression cassette and hybrid proteins. The reporter expression cassette encodes a reporter and comprises at least one DNA binding site. Each hybrid protein comprises a candidate binding partner and a component of a DNA binding protein and, upon association, form a DNA-binding complex capable of binding to the at least one binding site and inhibiting expression of the reporter. The methods, kits and cells find application, for example, in the identification of inhibitors that may be useful in treating diseases associated with protein aggregation, such as Alzheimer's Disease and Parkinson's Disease.

Resumen de: WO2023081422A1

The present invention provides methods and compositions for the treatment of subjects that have Dementia with Lewy Bodies (DLB) but have no substantial tau pathology. Subjects with DLB that have no substantial tau pathology are shown to be particularly responsive to treatment with a selective p38α mitogen activated protein kinase (MAPK) inhibitor compared to subjects with DLB that have substantial tau pathology.

Resumen de: KR20230064459A

본 발명은 아밀로이드 베타 멀티머 저해 약물 스크리닝용 키트 및 이를 이용한 알츠하이머병 예방 또는 치료용 약물의 고속 대량 스크리닝 방법에 관한 것이다. 보다 상세하게는, 본 발명의 아밀로이드 베타 멀티머 저해 약물 스크리닝용 키트를 사용하는 경우, 후보 물질로부터 아밀로이드 베타 멀티머 저해 효과가 있는 약물을 대량으로 빠르고 정밀하게 스크리닝할 수 있어, 알츠하이머병의 예방 또는 치료 약물을 발굴 및 선점하는 데 유용하게 사용될 수 있다.

Resumen de: WO2020260722A1

The invention relates to isolated recombinant peptides comprising an epitope from human tau 2N4R. The invention also relates to use of such peptides to generate binding molecules, such as antibodies, specific for the tau epitope and to such peptides and antibodies for use in investigation, diagnosis and treatment of tauopathies, such as Alzheimer's disease.

Resumen de: US2023133226A1

Aggregation-induced emission luminogens useful for imaging β-amyloid peptide and aggregates thereof, pharmaceutical compositions comprising the same, and methods of use and preparation thereof.

Resumen de: WO2023073384A1

The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.